Danaher Co. (NYSE:DHR) Shares Acquired by Parcion Private Wealth LLC

Parcion Private Wealth LLC grew its position in shares of Danaher Co. (NYSE:DHR) by 5.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 32,261 shares of the conglomerate’s stock after acquiring an additional 1,615 shares during the quarter. Danaher comprises 0.7% of Parcion Private Wealth LLC’s portfolio, making the stock its 25th biggest position. Parcion Private Wealth LLC’s holdings in Danaher were worth $8,969,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the business. Good Life Advisors LLC purchased a new stake in Danaher during the 3rd quarter worth $217,000. Oak Thistle LLC acquired a new stake in Danaher during the second quarter worth about $363,000. Norden Group LLC bought a new position in Danaher in the first quarter worth about $4,151,000. Duality Advisers LP acquired a new position in Danaher in the first quarter valued at approximately $5,573,000. Finally, Diversified Trust Co raised its position in shares of Danaher by 75.4% during the 2nd quarter. Diversified Trust Co now owns 4,360 shares of the conglomerate’s stock worth $1,090,000 after purchasing an additional 1,874 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Buying and Selling

In other news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Danaher news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the sale, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at $27,435,240. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 30,059 shares of company stock valued at $8,400,897. Company insiders own 11.10% of the company’s stock.

Danaher Trading Down 1.0 %

Shares of DHR stock opened at $245.41 on Friday. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The stock has a 50-day simple moving average of $269.52 and a 200 day simple moving average of $260.35. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $281.70. The stock has a market capitalization of $181.77 billion, a P/E ratio of 41.59, a P/E/G ratio of 4.49 and a beta of 0.83.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter in the prior year, the company earned $2.02 earnings per share. The firm’s revenue was up 3.1% on a year-over-year basis. On average, sell-side analysts expect that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were issued a dividend of $0.27 per share. The ex-dividend date of this dividend was Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. Danaher’s dividend payout ratio is currently 18.31%.

Wall Street Analyst Weigh In

A number of research analysts recently commented on DHR shares. Bank of America upped their price objective on Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. Stephens reaffirmed an “overweight” rating and issued a $315.00 price objective on shares of Danaher in a report on Wednesday. Stifel Nicolaus boosted their target price on shares of Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a research note on Wednesday. The Goldman Sachs Group raised their price target on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. Finally, Leerink Partners boosted their price objective on Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Seven equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $287.28.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.